Trametinib targeted drug price list in 2024

Trametinib is an oral anti-cancer drug that is a mitomycin kinase (MEK) inhibitor. It is designed to treat advanced or metastatic melanoma (skin cancer) with the BRAF V600E or V600K mutation and non-small cell lung cancer with the BRAF V600E mutation.

Currently, trametinib has been launched in China and is included in the scope of medical insurance. Patients can purchase this drug domestically, but the price is relatively high, about more than 10,000 yuan. Specific costs may vary by region and hospital. In foreign countries, the price of trametinib is relatively low. This is mainly due to the existence of many generic drugs, especially those produced in Laos and other places. The price is only about one to two thousand yuan, which is much cheaper than in China. However, it is worth noting that there is no significant difference in the pharmaceutical ingredients between these foreign generic drugs and domestic original drugs.

The mechanism of action of trametinib is to block abnormal signaling pathways by inhibiting the activity ofMEK protein kinase. In many tumors, BRAF gene mutations can lead to abnormal activity in cell signaling pathways and promote tumor growth and spread. The role of trametinib is to interfere with this abnormal activity, thereby inhibiting the proliferation and survival of tumor cells.

Specifically, the targeted effect of trametinib is to inhibit the proliferation of tumor cells by blocking theRAS/RAF/MEK/ERK signaling pathway. This signaling pathway is abnormally activated in many types of tumors, including melanoma and non-small cell lung cancer. The inhibitory effect of trametinib can slow or stop the growth of tumor cells, thereby prolonging patient survival and, in some cases, leading to tumor remission.

However, trametinib may also cause a series of side effects, including but not limited to skin rash, diarrhea, nausea, fatigue, headache, etc. Patients need to closely monitor these side effects while receiving trametinib and report them to their doctors in a timely manner so that the treatment plan can be adjusted or supportive care provided.

xa0